PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33597189-6 2021 Based on an analysis of individual treatments (interferon-beta, glatiramer acetate, fingolimod, and natalizumab), interferon-beta was associated with inferior RGC preservation, relative to the other drugs. Glatiramer Acetate 64-82 interferon beta 1 Homo sapiens 114-129 30075406-12 2018 The treatment with interferon-beta (IFN-beta) and glatiramer acetate (GA) was safe and patients treated with high dose IFN-beta and GA had a statistically significant reduction in disability progression. Glatiramer Acetate 50-68 interferon beta 1 Homo sapiens 119-127 26475277-1 2015 OBJECTIVE: The Escala Study evidenced that the administration of glatiramer acetate for relapsing-remitting multiple sclerosis improved the spasticity of patients previously treated with interferon-beta. Glatiramer Acetate 65-83 interferon beta 1 Homo sapiens 187-202 29139001-12 2018 The real-world assessment further demonstrated that IFN-beta-1a-IM users had a statistically higher risk of treatment failure, defined as treatment switching or relapse treatment or death, with the assessment showing that IFN-beta-1a-IM was inferior to the other IFN-betas and to glatiramer acetate in both direct and indirect analysis. Glatiramer Acetate 280-298 interferon beta 1 Homo sapiens 52-60 27063624-2 2016 Aim of this work was to quantitatively summarize by a meta-analysis the long-term impact of immunomodulatory drugs (Interferon-Beta (IFN-beta) or Glatiramer Acetate (GA)) in relapsing-remitting (RR) MS patients. Glatiramer Acetate 166-168 interferon beta 1 Homo sapiens 116-131 26475277-10 2015 The ratio of the costs during interferon-beta was 1.5 times the costs during glatiramer acetate; thus, a fixed budget of 5,000,000$ would enable 1,070 patients to be treated with glatiramer acetate and only 706 patients with interferon-beta. Glatiramer Acetate 179-197 interferon beta 1 Homo sapiens 30-45 25646307-5 2015 IFN-beta treatment increases the absolute number of regulatory CD19(+)CD24(++)CD38(++) transitional B cells in peripheral blood relative to treatment-naive and Copaxone-treated patients. Glatiramer Acetate 160-168 interferon beta 1 Homo sapiens 0-8 26374509-3 2015 Approximately 30% of patients treated with first-line immunomodulators (interferon-beta or glatiramer acetate) show a suboptimal response during the first 1-2 years and require a switch to an alternative therapy. Glatiramer Acetate 91-109 interferon beta 1 Homo sapiens 72-87 23650472-5 2012 Additionally, RRMS patients with suboptimal response to interferon beta may benefit from reduced relapse rate after switching to GA, and those with clinically isolated syndrome may benefit from delayed conversion to CDMS. Glatiramer Acetate 129-131 interferon beta 1 Homo sapiens 56-71 25182864-2 2014 Following recent regulatory approvals in the USA and European Union, IFN beta-1b is now one of the seven disease-modifying therapies [intramuscular IFN beta-1a; subcutaneous (SC) IFN beta-1a; IFN beta-1b SC; glatiramer acetate SC; oral dimethyl fumarate; oral teriflunomide; and intravenous alemtuzumab] indicated for first-line use in relapsing-remitting MS. Glatiramer Acetate 208-226 interferon beta 1 Homo sapiens 69-77 25170258-2 2014 Several clinical trials have shown consistent and sustained efficacy of glatiramer acetate 20 mg subcutaneously daily in reducing relapses and new demyelinating lesions on magnetic resonance imaging in patients with relapsing-remitting multiple sclerosis, as well as comparable efficacy to high-dose interferon beta. Glatiramer Acetate 72-90 interferon beta 1 Homo sapiens 300-315 22133480-1 2012 BACKGROUND: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment in multiple sclerosis (MS) patients who previously received interferon-beta (IFN-beta). Glatiramer Acetate 73-91 interferon beta 1 Homo sapiens 167-182 22133480-1 2012 BACKGROUND: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment in multiple sclerosis (MS) patients who previously received interferon-beta (IFN-beta). Glatiramer Acetate 73-91 interferon beta 1 Homo sapiens 184-192 22133480-1 2012 BACKGROUND: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment in multiple sclerosis (MS) patients who previously received interferon-beta (IFN-beta). Glatiramer Acetate 93-95 interferon beta 1 Homo sapiens 167-182 22133480-1 2012 BACKGROUND: A recent pilot study suggested spasticity improvement during glatiramer acetate (GA) treatment in multiple sclerosis (MS) patients who previously received interferon-beta (IFN-beta). Glatiramer Acetate 93-95 interferon beta 1 Homo sapiens 184-192 19921551-0 2009 [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis]. Glatiramer Acetate 1-19 interferon beta 1 Homo sapiens 23-38 20456216-2 2010 Prior to the United States Food and Drug Administration approval of the immunomodulatory agent, interferon-beta1b in 1993, no other drug had been shown to alter the course of the disease in a controlled study of MS. At present, there are five licenced disease-modifying agents in MS - interferon-beta1b, interferon-beta1a, glatiramer acetate, natalizumab and mitoxantrone. Glatiramer Acetate 323-341 interferon beta 1 Homo sapiens 96-112 20637960-19 2010 Furthermore, the results suggest that GA may reduce spasticity in patients previously treated with IFN-beta. Glatiramer Acetate 38-40 interferon beta 1 Homo sapiens 99-107 12474988-3 2002 IFNbeta has a significant anti-proliferative effect on GA-induced lymphoproliferation in vitro. Glatiramer Acetate 55-57 interferon beta 1 Homo sapiens 0-7 19200865-5 2009 There is some evidence that interferon-beta treatment may exacerbate depressive symptoms and a switch to glatiramer acetate can be envisaged in patients treated with an interferon-beta in whom depressive symptoms become an issue. Glatiramer Acetate 105-123 interferon beta 1 Homo sapiens 169-184 18164542-7 2008 Due to its lower efficacy, glatiramer acetate should be used as a second choice in case of intolerable side effects or toxicity of interferon beta. Glatiramer Acetate 27-45 interferon beta 1 Homo sapiens 131-146 18690500-0 2008 Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients. Glatiramer Acetate 0-18 interferon beta 1 Homo sapiens 71-86 18690500-2 2008 This is the first study that shows that switching patients from IFNbeta to glatiramer acetate (GA) in case of neutralising antibodies (NAb) positivity is effective in reducing relapse rate and in delaying the time to first relapse. Glatiramer Acetate 75-93 interferon beta 1 Homo sapiens 64-71 18690500-2 2008 This is the first study that shows that switching patients from IFNbeta to glatiramer acetate (GA) in case of neutralising antibodies (NAb) positivity is effective in reducing relapse rate and in delaying the time to first relapse. Glatiramer Acetate 95-97 interferon beta 1 Homo sapiens 64-71 16674604-0 2006 Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. Glatiramer Acetate 0-18 interferon beta 1 Homo sapiens 48-63 16674604-10 2006 Switching to GA can benefit patients who discontinue IFN-beta therapy. Glatiramer Acetate 13-15 interferon beta 1 Homo sapiens 53-61 16146492-1 2005 OBJECTIVES: Glatiramer acetate (GA) is routinely used in multiple sclerosis (MS) patients who cannot tolerate or fail to respond to beta-interferon (IFN-beta). Glatiramer Acetate 12-30 interferon beta 1 Homo sapiens 149-157 16146492-1 2005 OBJECTIVES: Glatiramer acetate (GA) is routinely used in multiple sclerosis (MS) patients who cannot tolerate or fail to respond to beta-interferon (IFN-beta). Glatiramer Acetate 32-34 interferon beta 1 Homo sapiens 149-157 12835817-10 2003 CONCLUSIONS: For a typical patient with RRMS, treatment with copaxone would be more efficient than interferons and would dominate (would be more efficacious with lower costs) interferon beta. Glatiramer Acetate 61-69 interferon beta 1 Homo sapiens 175-190 17516727-1 2004 BACKGROUND AND OBJECTIVE: During the last decade, several agents have proven to be effective in the treatment of relapsing-remitting multiple sclerosis (RRMS), for example interferon-beta (IFNbeta) and glatiramer acetate. Glatiramer Acetate 202-220 interferon beta 1 Homo sapiens 172-187 17516727-1 2004 BACKGROUND AND OBJECTIVE: During the last decade, several agents have proven to be effective in the treatment of relapsing-remitting multiple sclerosis (RRMS), for example interferon-beta (IFNbeta) and glatiramer acetate. Glatiramer Acetate 202-220 interferon beta 1 Homo sapiens 189-196 12521562-4 2003 In relapsing-remitting multiple sclerosis (RRMS), there is overwhelming Class I data from large clinical trials that supports the use of interferon-beta-1a (IFNbeta-1a), interferon-beta-1b (IFNbeta-1b), and glatiramer acetate. Glatiramer Acetate 207-225 interferon beta 1 Homo sapiens 137-152 12581542-4 2002 OBJECTIVE: This article reviews the potential mechanisms of action of IFN beta products and GA in the context of their regulatory effects on autoimmune components that may be of importance in MS. METHODS: MEDLINE and Current Contents/Clinical Medicine were searched for articles published in English from 1993 to the present using the search terms interferon beta, glatiramer acetate, and multiple sclerosis. Glatiramer Acetate 365-383 interferon beta 1 Homo sapiens 70-78 12474988-12 2002 The Th1/Th0/Th2 distribution of GA-TCL was 7%/30%/63% for the GA+IFNbeta group, 8%/9%/83% for the GA group, compared to 48%/21%/31% pre-GA treatment. Glatiramer Acetate 32-34 interferon beta 1 Homo sapiens 65-72 12349849-0 2002 Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Interferon-beta and glatiramer acetate (GA) are the two main groups of drugs used in the treatment of MS. Glatiramer Acetate 122-124 interferon beta 1 Homo sapiens 37-52 12349849-0 2002 Differential mechanisms of action of interferon-beta and glatiramer aetate in MS. Interferon-beta and glatiramer acetate (GA) are the two main groups of drugs used in the treatment of MS. Glatiramer Acetate 102-120 interferon beta 1 Homo sapiens 37-52